Search

Your search keyword '"Putnam, B"' showing total 173 results
Start Over Author "Putnam, B"
173 results on '"Putnam, B"'

33. Racially different adolescents: self-concepts and vocational attitudes.

Author

Rosenthai, D. M., Putnam, B. A., and Ansen, J. C.

Abstract

"This research examines the self-concepts, vocational attitudes, and vocational preference similarities and differences of a culturally representative group of black and white urban adolescents." Specifically, the authors attempted to answer the following questions: "Are there significant differences in self-concept and vocational attitude maturity between black and white adolescents according to different vocational preference categories? Are there significant racial differences in self-concept and vocational maturity during the school years eight through twelve? To answer the questions, the authors used subjects from four urban junior high schools and two urban senior high schools. The instruments employed were the Tennessee Self Concept Scale, the Vocational Maturity Attitude Inventory, and Vocational Preference Inventory. They concluded that "there are racial differences in career maturity in urban adolescents, and … there are no significant self-concept differences in the sample population."

Published
1979

34. SECTION NUMBER VII PAIRS OF COUNTRIES AND CRISIS AREAS: SYSTEM NUMBER VII-23: BRITAIN AND THE MIDDLE EAST.

Author

Henderson, B., Putnam, B., and Pickett, Ralph H.

Abstract

Several abstracts of reference sources on Great Britain-Middle East relations published as of November 1969 are presented, including an opinion piece on British troop withdrawal from Aden, an article on Iraq's relations with the West and survey of the Anglo-Yemeni relations from the perspective of the Southern Yemen claim from 1900 to 1967.

Published
1969

36. Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370

Author

Ickovics, Jeannette R, Cameron, Ann, Zackin, Robert, Bassett, Roland, Chesney, Margaret, Johnson, Victoria A, Kuritzkes, Daniel R, Acosta, E, Barnett, R, Bell, D, Cannmann, S, Eron, J, Fischl, M, Marschner, I, Martinez, A, Morse, G, Pettinelli, C, Sommadossi, J-P, Wood, K, Murphy, R, Priller, N, Sha, B, French, N, van der Horst, C, Marcus, C, Lane, T, Horton, J, Schooley, R, Putnam, B, Shugarts, D, Johnson, S, Fife, K, Black, J, Heise, D, Todd, K, Bagur, JL Santana, Vazquez, GJ, Lopez, I, Ramirez, V, Hill, R, Wright, S, McCulloch, B, Saag, M, Slamowitz, D, Cain, P, Merigan, TC, Tallman, V, Greisberger, C, Shoemaker, M, Lewis, M, Hewitt, R, Havlir, D, Nuffer, K, Wininger, DA, Watson, S, Clark, J, Jackson, C, Rodriguez, A, Scerpella, E, Tebas, P, Stiffler, T, Royal, M, Powderly, WG, Collier, A, Storey, S, Houseworth, L, Conley, NJ, Lederman, M, Kalayjian, B, Ingersol, K, McVey, R, Gluckman, S, Helker, CP, Kappes, R, Kim, D, Albrecht, M, Koziol, C, Govan;, T, Miles, S, Chafey, S, Mitsuyasu, R, Sacks, H, Mildvan, D, Shikuma, C, Millard, M, and Souza, S

Abstract

Objectives (1) To document rates and patterns of adherence from enrollment until week 24 of an AIDS clinical trial; (2) to examine the association of adherence to clinical end-points including plasma HIV-1 RNA level and CD4 cell count; and (3) to identify predictors of adherence from clinical, behavioural, psychosocial and demographic factors.Design Sub-study of a multicentre, randomised, open-label, comparison-controlled trial; 21 collaborating units of the Adult AIDS Clinical Trials Group. Observational, prospective analysis.Methods Ninety-three subjects with baseline plasma HIV-1 RNA levels >500 copies/ml, who completed clinical assessment, plasma HIV-1 RNA titres and CD4 cell counts at study entry, weeks 2, 4 and every 4 weeks thereafter until week 24. All patients were antiretroviral-experienced but were naive to non-nucleoside reverse transcriptase inhibitors and protease inhibitors. Self-reported adherence to antiretroviral therapies prescribed as part of the trial was assessed every 4 weeks from trial, week 4 until week 24.Results Average adherence was high, with 63% of subjects reporting >95% adherence across the trial. However, there was a significant decline in adherence over time on trial. After controlling for potential confounding variables, patients who were less than 95% adherent to medications were 3.5-times more likely to have treatment failure (HIV-1 RNA >50 copies/ml) than subjects with adherence rates of 95–100%. The strongest predictor of adherence was adverse clinical events (for example, dermatological, gastrointestinal symptoms): patients with adverse events were 12.8-times less likely to have 95–100% adherence. Other clinical, demographic, psychosocial and behavioural factors were also significant predictors of adherence.Conclusions Adherence influences virological outcome even in AIDS clinical trials where overall adherence rates are high and should therefore be monitored in future trials. Intervention may be warranted to enhance adherence for subjects who have early toxicities, express concern about taking medications as directed, and for women and minorities.

Published
2002
Full Text
View/download PDF

37. OBITUARY

Author

PUTNAM, B. H., CAM, HELEN, IRWIN, RAYMOND, GIUSEPPI, J. A., and DARWIN, K.

Published
1960
Full Text
View/download PDF

40. What do we know about the explosibility of coal dust in mines?

Author

Greenwald, H. P., Greenwald, H.P. (Harold Putnam), b. 1893., Greenwald, H. P., and Greenwald, H.P. (Harold Putnam), b. 1893.

Abstract

We have determined this item to be in the public domain according to US copyright law through information in the bibliographic record and/or US copyright renewal records. The digital version is available for all educational uses worldwide. Please contact HathiTrust staff at hathitrust-help@umich.edu with any questions about this item., Mine explosions., Coal mines and mining., (OCoLC)40870393., Sdr-gwlaocm40870393., Http://hdl.handle.net/2027/mdp.39015077570185.

Published
1929

46. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

Author

Firnhaber, C., Torres, M., Santos, B., Webb, N., Mildvan, D., Nair, A., Hoffman, I., McGregor, D., Chariyalertsak, S., Stroberg, T., Martinez, A.I., Infante, R., Para, M.F., Hurley, C., Marcus, C.J., Poongulali, S., Eshleman, S., Andrade, A., Lira, R.A., Tashima, K.T., Lawrence, J., Cohen, M., Swann, E., Noel-Connor, J., Steele, J., Mitsuyasu, R.T., Lalloo, U., Cu-Uvin, S., Riviere, C., Amod, F., Shugarts, D.L., Descallar, R.S., Klingman, K.L., Gormley, J., Corales, R., Luque, A., Smeaton, L.M., Currier, J.S., Said, F., Haas, D.W., Campbell, T.B., Dhayarkar, S., Celentano, D., Sanne, I., Tabet, S., Jain, M., Daar, E.S., Kumwenda, N., Revuelta, M., Kayoyo, V., Feinberg, J., Taha, T., Chilongozi, D., Kazembe, P., Cardoso, S.W., Martinson, F., Berendes, S., Faesen, S., Schooley, R.T., Flanigan, T., Bischofberger, N., Walawander, A., Kumwenda, J., Supparatpinyo, K., Lama, J.R., Pappa, K.A., Klebert, M.K., Severe, P., Berthaud, V., Solomon, S., Petersen, T., la Rosa, A., Frarey, L., Cheng, A., van der Horst, C., Barnett, R.L., Sharma, J., Putnam, B., Fiscus, S.A., Chen, Y., Gaikwad, A., Brizz, B., Chisada, A., Cox, G.M., Uy, J., Adams, M., Moran, L., Bailey, V.L., Rooney, J.F., Snowden, W., Pollard, R.B., Wulfsohn, M., Mayer, K., Gettinger, N., Watson, K.J., Sha, B.E., Ray, M.G., Hakim, J.G., Palmer, M., Kim, G.-Y., Basler, C., Lopez-Detres, L., Samaneka, W.P., Bollinger, R.C., Delph, Y., Wanke, C., Bryson, Y., Faria, D.L., Mogridge, C., Taiwo, B., Nielsen, K., Forcht, J., Winters, M.A., de Gruttola, V., Tebas, P., Lopez, R., Ntshele, S., Asmuth, D., Godbole, S., Patterson, H., Flexner, C., Eron, J., Collier, A.C., Ramratnam, B., Tripathy, S., Jaffe, H., Balfour, H.H., Zifchak, L., Kumarasamy, N., Haas, D.H., Fritsche, J.M., Currin, D., Grinsztejn, B., Mngqibisa, R., Gangakhedkar, R.R., Gallant, J.E., Martin, J.C., Safren, S., Silberman, M., Mullan, B., Geiseler, P.J., Joglekar, A.A., Cespedes, M., Kanyama, C., Gulick, R.M., Burke, K., Maponga, C., Loeliger, E., Hosseinipour, M.C., Baer, J., OBrien, W.A., Melo, M., Pendame, R.B., Hammer, S.M., Sanchez, J., and Sirisanthana, T.

Subjects
virus diseases, 3. Good health
Abstract

Background:Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.Methods and Findings:1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the hazard ratio (HR) was ≤1.35 when 30% of participants had treatment failure.An independent monitoring board recommended stopping study follow-up prior to accumulation of 472 treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72-1.27; p = 0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p

Catalog

Books, media, physical & digital resources
See catalog results